GlassScriptPhysician profile
Nasrin Esnaashari
NPI 1831389477
$9,130.36
in general payments reported to CMS, 2019-2025
10 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,989 · 2022: $22.70 · 2023: $3,866 · 2024: $800 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730 · Travel and Lodging: $2,546 · Honoraria: $1,170 · Consulting Fee: $600 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.18 |
| Travel and Lodging | $2,546.10 |
| Honoraria | $1,170.00 |
| Consulting Fee | $600.00 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,047.96 | 2021-2025 | General - Dbs |
| Abbott Laboratories | $2,826.03 | 2021-2025 | Infinity |
| Mdd US Operations, LLC | $1,893.08 | 2025 | Gocovri |
| Medtronic, INC. | $750.26 | 2023-2025 | Percept PC Brainsense |
| Abbvie INC. | $279.44 | 2023-2025 | |
| Eisai INC. | $121.96 | 2023 | |
| Neurocrine Biosciences, INC. | $99.99 | 2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $59.04 | 2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $29.90 | 2023 | Austedo Xr |
| Allergan, INC. | $22.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasrin Esnaashari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.